Daraxonrasib Approved for Metastatic Pancreatic Cancer
Key Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreKey Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreKey Points Researchers at Trinity College Dublin published a major review explaining why pancreatic cancer remains highly resistant to treatment.
Read MoreCedars-Sinai Cancer researchers used the Molecular Twin Precision Oncology Platform, a novel precision medicine and artificial intelligence (AI) platform, to
Read MoreOHSU researchers are contributing experience, new ideas, and a three-pronged strategy to a National Cancer Institute cooperative for early cancer
Read More